People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...